U.S. Markets closed

Gilead Reverses After Liver-Disease Treatment Fails Its Second Key Test

ALLISON GATLIN
Gilead Reverses After Liver-Disease Treatment Fails Its Second Key Test

Gilead Sciences said Thursday its liver disease medicine failed in a Phase 3 test — two months after the same drug flunked in a sicker group of patients. But Gilead stock rose more than 2%.